Organogenesis Holdings Inc. announced the appointment of Prathyusha Duraibabu to the Company?s Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. Ms. Duraibabu currently serves as the Chief Financial Officer of Sangamo Therapeutics, a clinical stage biopharmaceutical company with a robust genomic medicines pipeline. Prior to joining Sangamo, Ms. Duraibabu was Corporate Controller at Pacific Biosciences of California Inc. from 2010 to 2019, a leading commercial DNA sequencing instrument company. Ms. Duraibabu began her career as an international tax and audit professional and served in a variety of accounting and finance roles of increasing responsibility for companies in the software and semiconductor sectors. She holds a Bachelors of Accounting from Oxford Brookes University, and an MBA from San Jose State University. She is a Certified Public Accountant.